“…De novo drug design (Hartenfeller and Schneider, 2010) through existing computer technology can speed up drug development and save research costs. The tasks involved in de novo drug design include molecular generation (Gómez-Bombarelli et al, 2016;Cao and Kipf, 2018;Jin et al, 2018;You et al, 2018;Madhawa et al, 2019;Popova et al, 2019;Zhang et al, 2019;Hong et al, 2020;Zang and Wang, 2020;Bagal et al, 2021), drug and drug interactions (DDI) (Li et al, 2021;Lin et al, 2021;Lyu et al, 2021;Zhao et al, 2021), disease associations (Ding et al, 2020;Lei and Zhang, 2020;Mudiyanselage et al, 2020;Lei X.-J. et al, 2021;Lei X. et al, 2021;Wang Y. et al, 2021;Lei and Zhang, 2021;Yang and Lei, 2021;Zhang et al, 2021), and so on.…”